Allison Zavitz

Company: Roche

Job title: Lifecycle Leader, KRAS

Seminars:

From Conception to Accessible: Making Strategic Decisions About the Development, Adoption & Promotion of RAS-Targeted Therapies 3:01 pm

With two approved therapies (Sotorasib and Adagrasib), the field has certainly achieved the monumental task of validating RAS as a “druggable” target. However, the landscape of RAS drugs stretches from conception to phase 3 clinical trials. Making the right decisions to develop your drug before approval, and then make it accessible to patients after approval…Read more

day: Workshop F